The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
METHYLPHENIDATE — Methylphenidate is effective in reducing the symptoms of ADHD in both children and adults.1,2 The effects of immediate-release methylphenidate products on behavior begin within 30 minutes and last for 3-5 hours; repeat dosing at mid-day is usually required. Long-acting methylphenidate products are dosed once daily. Some generic formulations of Concerta, which has a duration of action of 10-12 hours, have been found to release the drug at a slower rate after 7 hours and may have a shorter duration of...
- Drugs for Insomnia
- Liletta - A Third Levonorgestrel-Releasing IUD
- Ryanodex - A New Dantrolene Formulation for Malignant Hyperthermia
- Eliglustat (Cerdelga) - An Oral Drug for Gaucher Disease (online only)
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
STANDARD TREATMENT — Patients with symptomatic heart failure with reduced ejection fraction generally take an angiotensin-converting enzyme (ACE) inhibitor, a beta blocker, and an aldosterone antagonist. If volume overloaded, they may take a diuretic as well. An ARB is recommended for patients who cannot tolerate an ACE ...